Table 5

Diagnostic profiles of VEGF levels available before second and third cycles of chemotherapy for the prediction of cancer progression or response to therapy

AUC

Cut-off

Sensitivity %

Specificity %

LR

(95% CI)

VEGF (pg/mL)

(95% CI)

(95% CI)

Evaluation 1 (R + NC vs P)

VEGF BV2

0.805 (0.675-0.935)

312.6

71.4 (42.0-90.4)

71.4 (51.1-86.0)

2.5

VEGF BV3

0.895 (0.797-0.993)

355.4

85.7 (56.2-97.5)

89.3 (70.6-97.2)

8.0

Evaluation 2 (R vs NC + P)

VEGF BV2

0.724 (0.553-0.893)

232.1

76.9 (55.9-90.2)

75.0 (47.4-91.7)

3.1

VEGF BV3

0.817 (0.679-0.956)

261.0

76.9 (55.9-90.2)

75.0 (47.4-91.7)

3.1

BV2, and BV3, baseline VEGF levels before therapy cycle 2 to 3, respectively; AUC, area under receiver operating characteristic

(ROC) curve; 95% CI, 95% confidence interval; LR, likelihood ratio; R, remission; NC, no change; P, progression.

Kumar et al. BMC Cancer 2009 9:421   doi:10.1186/1471-2407-9-421